KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Gains from Investment Securities: 2011-2019

Historic Gains from Investment Securities for Esperion Therapeutics (ESPR) over the last 9 years, with Dec 2019 value amounting to $4.7 million.

  • Esperion Therapeutics' Gains from Investment Securities fell 14.00% to $4.6 million in Q2 2020 from the same period last year, while for Jun 2020 it was $4.6 million, marking a year-over-year decrease of 14.00%. This contributed to the annual value of $4.7 million for FY2019, which is 11.80% down from last year.
  • Latest data reveals that Esperion Therapeutics reported Gains from Investment Securities of $4.7 million as of FY2019, which was down 11.80% from $5.3 million recorded in FY2018.
  • In the past 5 years, Esperion Therapeutics' Gains from Investment Securities registered a high of $7.4 million during FY2015, and its lowest value of $400,000 during FY2016.
  • For the 3-year period, Esperion Therapeutics' Gains from Investment Securities averaged around $4.7 million, with its median value being $4.7 million (2019).
  • As far as peak fluctuations go, Esperion Therapeutics' Gains from Investment Securities plummeted by 94.59% in 2016, and later surged by 900.00% in 2017.
  • Yearly analysis of 5 years shows Esperion Therapeutics' Gains from Investment Securities stood at $7.4 million in 2015, then plummeted by 94.59% to $400,000 in 2016, then surged by 900.00% to $4.0 million in 2017, then spiked by 32.59% to $5.3 million in 2018, then dropped by 11.80% to $4.7 million in 2019.